The title thia-pyrazino-phanes, 2,5,8,11,14,17-hexa-thia-[9.9](2,6,3,5)-pyrazino-phane, CHNS, (), and 2,5,8,11,14,17-hexa-thia-[9.9](2,5,3,6)-pyrazino-phane, CHNS, (), are regioisomers; -bis L1 and -bis L1, respectively. Both compounds have a central tetra-2,3,5,6-methyl-ene-pyrazine unit with two -S-CH-CH-S-CH-CH-S- chains, linking the methyl-ene C atoms at positions 2 and 6 and 3 and 5 on the pyrazine ring of , but linking the methyl-ene C atoms at positions 2 and 5 and 3 and 6 on the pyrazine ring of . Both compounds crystallize with half a mol-ecule in the asymmetric unit. The whole mol-ecule of is generated by inversion symmetry, with the pyrazine ring being located about a center of symmetry. The whole mol-ecule of is generated by twofold rotation symmetry, with the pyrazine N atoms being located on the twofold rotation axis. In compound , there are pairs of intra-molecular C-H⋯S contacts present, but none in compound . In the crystal of , there are no significant inter-molecular inter-actions present, while in the crystal of , mol-ecules are linked by pairs of C-H⋯S hydrogen bonds, forming corrugated layers lying parallel the plane. The Hirshfeld surfaces and the energy frameworks of the two regioisomers indicate little difference in the inter-atomic contacts, which are dominated by dispersion forces.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336784 | PMC |
http://dx.doi.org/10.1107/S2056989020007057 | DOI Listing |
Nat Phys
November 2024
Laboratory of Physical Chemistry, ETH Zürich, Zurich, Switzerland.
A dynamical rearrangement in the electronic structure of a molecule can be driven by different phenomena, including nuclear motion, electronic coherence or electron correlation. Recording such electronic dynamics and identifying its fate in an aqueous solution has remained a challenge. Here, we reveal the electronic dynamics induced by electronic relaxation through conical intersections in both isolated and solvated pyrazine molecules using X-ray spectroscopy.
View Article and Find Full Text PDFJ Hematol Oncol
December 2024
Experimentelle Unfallchirurgie (ForMED), Justus-Liebig-Universität Gießen, Aulweg 128, 35392, Gießen, Germany.
Background: Accumulation of malignant plasma cells in the bone marrow causes lytic bone lesions in 80% of multiple myeloma patients. Frequently fracturing, they are challenging to treat surgically. Myeloma cells surviving treatment in the presumably protective environment of bone lesions impede their healing by continued impact on bone turnover and can explain regular progression of patients without detectable minimal residual disease (MRD).
View Article and Find Full Text PDFJ Cell Mol Med
December 2024
Menarini Group, Preclinical and Translational Sciences, Pomezia, Rome, Italy.
MEN1703 is a first-in-class, oral, Type I dual PIM/FMS-like tyrosine kinase 3 inhibitor (FLT3i) investigated in a Phase I/II DIAMOND-01 trial in patients with acute myeloid leukaemia (AML). Gilteritinib is a highly potent and selective oral FLT3i approved for the treatment of relapsed/refractory AML with FLT3 mutations. Although gilteritinib showed strong single-agent activity in FLT3-mutated AML, the development of gilteritinib resistance limits response durability, indicating the importance of novel combination strategies to improve disease outcome.
View Article and Find Full Text PDFCell Biol Toxicol
November 2024
Suzhou Medical College of Soochow University, Suzhou City, 215123, Jiangsu Province, P.R. China.
Background: Gilteritinib is a commonly used targeted drug for acute myeloid leukemia (AML), but the emergence of gilteritinib resistance greatly reduces the therapeutic effect. RING finger protein 38 (RNF38), a protein with RING Finger domain and E3 ubiquitin ligase activity, has been implicated in tumorigenesis and drug resistance. However, the role and mechanism of RNF38 in the gilteritinib resistance of AML remains unclear.
View Article and Find Full Text PDFJ Am Chem Soc
December 2024
Department of Chemistry, Faculty of Pure and Applied Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!